SJ Ryan Arends, PhD

Principal Scientist
JMI Laboratories

Disclosure(s): AbbVie: Grant/Research Support; GSK: Grant/Research Support; Nabriva Therapeutics: Grant/Research Support; Shionogi: Grant/Research Support

Poster(s):

641 - Activity of Gepotidacin Tested Against Molecularly Characterized Escherichia coli Isolates Resistant to Commonly Used Oral Therapies for UTI in the US (2019-2020)
Thursday, October 20, 2022
12:15 PM – 1:30 PM US ET
656 - Comparative Activity of Newer β-Lactam/β-Lactamase Inhibitor Combinations against Pseudomonas aeruginosa isolates from United States Medical Centers (2020-2021)
Thursday, October 20, 2022
12:15 PM – 1:30 PM US ET
1675 - Activity of Gepotidacin Against Escherichia coli Isolates from Community-acquired Urinary Tract Infections Collected Between 2019-2021 in the United States
Saturday, October 22, 2022
12:15 PM – 1:30 PM US ET
1676 - Activity of SPR206 and Comparator Agents Against Pseudomonas aeruginosa and Acinetobacter baumannii Causing Infections in United States Hospitals
Saturday, October 22, 2022
12:15 PM – 1:30 PM US ET
1677 - In vitro Activity of SPR206 and Comparator Compounds against Enterobacterales Isolates Responsible for Infections in United States Hospitals
Saturday, October 22, 2022
12:15 PM – 1:30 PM US ET
1684 - Antimicrobial Activity of Aztreonam-Avibactam Against a Large Collection of Stenotrophomonas maltophilia and Burkholderia cepacia Species Complex Causing Infections in United States (US) Medical Centers (2016-2021)
Saturday, October 22, 2022
12:15 PM – 1:30 PM US ET
1689 - In Vitro Activity of Lefamulin Against Bacterial Pathogens Collected From Pneumonia Patients in United States and Latin America Medical Centers in 2020-2021
Saturday, October 22, 2022
12:15 PM – 1:30 PM US ET